-
CDM Monthly Review
Greetings to all experts and colleagues. In this issue of the CDM Monthly Review, we will share six recent articles in the field of portal hypertension diagnosis and treatment (four on diagnostic monitoring and two on multidisciplinary treatment). This issue features reviews by invited experts: Professor Pengyuan He from the Center for Infectious Disease Control…
-
BOC/BOA 2024丨Professor Chaosu Hu: Advances in Immunotherapy and Proton Carbon Ion Therapy for Head and Neck Tumors
Traditional treatment for head and neck tumors mainly involves surgery, radiotherapy, and chemotherapy. In recent years, immune checkpoint inhibitors have shown promising potential in treating head and neck squamous cell carcinoma, and new radiotherapy techniques such as proton and carbon ion therapy offer treatment options with reduced radiation toxicity for patients with head and neck…
-
Professor Uwe Platzbecker: Breakthrough Progress in the Treatment of Acute Promyelocytic Leukemia (APL) — Key Findings from the APOLLO Study
Acute promyelocytic leukemia (APL) is a highly aggressive blood disorder, and its treatment has always been a challenge in the field of hematology. Chinese scholars have contributed the arsenic trioxide (ATO) regimen for global APL patients. Since the APL0406 study reported in the New England Journal of Medicine in 2013, all-trans retinoic acid (ATRA) combined…
-
BOC/BOA 2024丨New Breakthroughs in ADC Drugs for Breast Cancer Treatment—Professor Ying Fan Interprets the DB-06 and OptiTROP-Breast01 Studies
In the field of breast cancer treatment, the rapid development of antibody-drug conjugates (ADCs) is gradually changing the traditional treatment landscape, bringing more hope to patients. The presentation of the DB-06 and OptiTROP-Breast01 studies at the 2024 ASCO conference has elevated the application of ADC drugs in breast cancer treatment to a new level. At…
-
First Immunotherapy Combined with ADC Neoadjuvant Treatment for MIBC Revealed, Meeting the Survival Needs of More Patients
The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting was held from May 31 to June 4 in Chicago, USA, showcasing numerous cutting-edge research findings that will further advance the diagnosis and treatment practices in the field of urological tumors. Among them, a multicenter Phase II clinical study conducted in China, led by Peking…
-
BOC/BOA 2024丨Professor Yu Chen: Exploring New Strategies for Melanoma Treatment and Tackling Immunotherapy Resistance
Melanoma is one of the more common malignant tumors clinically. In recent years, although immunotherapy has brought new hope to melanoma patients, the issue of resistance has become increasingly prominent. At the 2024 Annual Progress Seminar of Chinese Clinical Oncology (BOC) and Beast of ASCO® 2024 China (BOC/BOA 2024), Professor Yu Chen from Fujian Cancer…
-
Professor Pei Dong: Continuously Exploring Individualized Treatment Strategies for Advanced Kidney Cancer in China
Kidney cancer is one of the three major tumors of the urinary system. According to statistics, in 2022, there were approximately 77,000 new cases and 46,000 deaths from kidney cancer in China. The prognosis for advanced metastatic kidney cancer is poor, with a five-year overall survival rate of less than 20% with targeted therapy alone.…
-
Prophylactic Infusion of Donor-Derived CD7 CAR-T Cells Post-Allo-HSCT for Treating R/R T-ALL/LBL
Recent clinical studies have shown that CD7-targeted chimeric antigen receptor T-cell (CAR-T) therapy is effective and safe for patients with T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LBL). Combining CAR-T therapy with transplantation has the potential to enhance treatment efficacy and reduce disease recurrence. Most existing studies have implemented CD7 CAR-T cells as a bridge to allogeneic hematopoietic…
Connecting Medical Expertise through Media